Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects ≥18 Years of Age With Persistent Asthma
Brief Summary: The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects ≥18 years of age who are currently receiving inhaled corticosteroid treatment.


Options:
A: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)
B: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): arm 2 | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): arm 1
C: Arm Label: C/E/A/B/D; Type: EXPERIMENTAL; Interventions: Drug: Dose 2 QD | Arm Label: D/C/E/A/B; Type: EXPERIMENTAL; Interventions: Drug: Dose 3 QD | Arm Label: A/B/C/D/E; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: B/A/D/E/C; Type: EXPERIMENTAL; Interventions: Drug: Dose 1 BD | Arm Label: E/D/B/C/A; Type: EXPERIMENTAL; Interventions: Drug: Dose 4 QD | Intervention Type: DRUG; Name: Dose 4 QD; Assigned to Arm(s): E/D/B/C/A | Intervention Type: DRUG; Name: Dose 3 QD; Assigned to Arm(s): D/C/E/A/B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A/B/C/D/E | Intervention Type: DRUG; Name: Dose 2 QD; Assigned to Arm(s): C/E/A/B/D | Intervention Type: DRUG; Name: Dose 1 BD; Assigned to Arm(s): B/A/D/E/C
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo

Answer: C